Merilog 100units/mL is supplied as both a 10mL multi-dose vial as well as a 3mL single-patient-use prefilled pen. The Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj), a ...
Kirsty 100units/mL is supplied as a 3 mL single-patient-use prefilled pen as well as a 10 mL multiple-dose vial. The approval of insulin aspart-xjhz was supported by a comprehensive data package that ...
Merilog, a biosimilar to Novolog, offers a more affordable insulin option for type 2 diabetes patients, enhancing treatment accessibility. The GEMELLI-1 trial confirmed Merilog's noninferiority to the ...
On February 14, 2025, the U.S. Food and Drug Administration (“FDA”) approved Sanofi-Aventis U.S. LLC’s (“Sanofi”) MERILOG™ (insulin-aspart-szjj), a biosimilar to Novo Nordisk A/S’s (“Novo Nordisk”) ...
NovoLog (insulin aspart) is a prescription medication used to manage blood sugar levels in people with type 1 or type 2 diabetes. NovoLog dosage varies based on individual factors such as the type of ...
More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency has ...
The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and children with diabetes, the agency announced Friday. Like its reference ...
NovoLog is a mealtime (rapid-acting) insulin. It’s a brand-name form of insulin aspart. For type 1 diabetes, you’ll typically inject NovoLog before your meals throughout the day. For type 2 diabetes, ...
NovoLog (insulin aspart) and Humalog (insulin lispro) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat type 1 and type 2 diabetes in certain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results